Related Experiment Video
Updated: Jan 8, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis
Tianwei Chen1,2, Yebin Yang3, Xiaoli Liu4
1Zhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. chentianwei@sibs.ac.cn.
Abstract:
Peritoneal metastasis (PM) poses a significant clinical challenge, yet the patient characteristics and genomic drivers underlying PM remain poorly characterized. Leveraging the MSK-MetTropism cohort (n = 25,755), our pan-cancer analysis reveals PM occurs in 29% of metastatic patients with extreme incidence variation (1% in THPA to 92% in HGSOC), and digestive/gynecologic malignancies exhibit the highest PM propensity with significant sex disparities. PM confers worse survival in 11/39 subtypes. Genomic profiling of 5,942 PM patients identifies enriched mutations in ESR1, TCF7L2, and FBXW7, pathway-level of TGF-Beta mutation, and subtype-specific drivers, including RET mutations in gastric PM. Mutational signatures implicate ROS (SBS18), HR deficiency (SBS3), and SBS8 across ≥9 cancer types. These results establish foundational insights into PM biology, though future PM tissue profiling is warranted to overcome primary tumor bias in genomic data.
Insights
Peritoneal metastasis (PM) affects 29% of metastatic patients, varying by cancer type and showing sex disparities. Genomic analysis reveals key mutations and mutational signatures driving PM, offering insights into its biology.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- Peritoneal metastasis (PM) is a significant clinical challenge with poorly understood patient characteristics and genomic drivers.
- Existing genomic data for PM may be biased by primary tumor profiling.
Purpose of the Study:
- To characterize patient demographics and genomic drivers of peritoneal metastasis across a large pan-cancer cohort.
- To identify specific mutations and mutational signatures associated with PM development and outcomes.
Main Methods:
- Utilized the MSK-MetTropism cohort (n=25,755) for pan-cancer analysis of PM incidence.
- Performed genomic profiling on 5,942 PM patients.
- Analyzed mutational signatures in relation to PM across multiple cancer types.
Main Results:
- PM incidence varies widely (1%-92%) across cancer types, with digestive and gynecologic malignancies showing high propensity and sex disparities.
- PM is associated with worse survival in 11/39 subtypes.
- Identified enriched mutations (ESR1, TCF7L2, FBXW7), TGF-Beta pathway mutations, and subtype-specific drivers (e.g., RET in gastric PM).
- Mutational signatures implicated ROS (SBS18), HR deficiency (SBS3), and SBS8 across multiple cancer types.
Conclusions:
- Established foundational insights into the biology of peritoneal metastasis.
- Highlighted the need for future PM tissue profiling to overcome primary tumor bias in genomic data.
- Demonstrated significant variation in PM incidence, associated survival impacts, and distinct genomic drivers across cancer types.
